RETRACTED ARTICLE: Long non-coding RNA VPS9D1-AS1 promotes growth of colon adenocarcinoma by sponging miR-1301-3p and CLDN1

Liu, Wei

doi:10.1007/s13577-021-00604-1

Cited by 8 publications

(10 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the lncRNA VPS9D1-AS1 was significantly upregulated in esophageal squamous cell carcinoma, which can promote the malignant progression of esophageal squamous cell carcinoma through the Wnt/catenin signaling pathway ( Ma et al, 2021 ). In colon adenocarcinoma, VPS9D1-AS1 can upregulate CLDN1 by sponging miR-1301-3p, thus facilitating colon adenocarcinoma cell growth suppressing apoptosis ( Liu, 2021 ). More importantly, we preliminarily measured the expression of these signature lncRNAs in OS cell lines and osteoclast cells.…”

Section: Discussionmentioning

confidence: 99%

A novel necroptosis-related lncRNAs signature effectively predicts the prognosis for osteosarcoma and is associated with immunity

Feng

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Necroptosis is closely related to tumorigenesis and development. Accumulating evidence has revealed that long non-coding RNAs (lncRNAs) are also central players in osteosarcoma (OS). However, the role of necroptosis-related lncRNAs in OS remains unclear. In the present study, we aim to craft a prognostic signature based on necroptosis-related lncRNAs to improve the OS prognosis prediction.Methods: The signature based on necroptosis-related lncRNAs was discovered using univariate Cox, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis. The prognosis efficiency of the signature was then estimated by employing various bioinformatics methods. Subsequently, immunological analysis and Gene Set Enrichment Analysis (GSEA) were used to explore the association between necroptosis-related lncRNAs with clinical outcomes and immune status. More importantly, several necroptosis-related lncRNAs were validated with RT-qPCR.Results: Consequently, a novel prognosis signature was successfully constructed based on eight necroptosis-related lncRNAs. Meanwhile, the novel necroptosis-related lncRNAs model could distribute OS patients into two risk groups with a stable and accurate predictive ability. Additionally, the GSEA and immune analysis revealed that the necroptosis-related lncRNAs signature affects the development and prognosis of OS by regulating the immune status. The necroptosis-related lncRNA signature was closely correlated with multiple anticancer agent susceptibility. Moreover, the RT-qPCR results indicated several necroptosis-related lncRNAs were significantly differently expressed in osteosarcoma and osteoblast cell lines.Conclusion: In this summary, a novel prognostic signature integrating necroptosis-related lncRNAs was firstly constructed and could accurately predict the prognosis of OS. This study may increase the predicted value and guide the personalized chemotherapy treatment for OS.

show abstract

Section: Discussionmentioning

confidence: 99%

A novel necroptosis-related lncRNAs signature effectively predicts the prognosis for osteosarcoma and is associated with immunity

Feng

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Studies have shown that miR-1301 is down-regulated in 11 cancers. These tumors include esophageal cancer ( 12 , 38 , 39 ), oral squamous cell carcinoma (OSCC) ( 13 ), colorectal cancer (CRC) ( 6 , 17 , 18 , 40 ), laryngeal squamous cell carcinoma (LSCC) ( 41 ), papillary thyroid carcinoma (PTC) ( 7 , 23 , 42 ), clear cell renal cell carcinoma (ccRCC) ( 27 ), bladder cancer ( 28 ), cervical cancer ( 33 ), glioma ( 4 , 24 , 29 ), osteosarcoma ( 8 , 9 , 43 ), and CML ( 10 ). In these tumors, miR-1301 is regulated by at least 12 ncRNAs, including 3 circRNAs (MYLK, circ_0004370 and circ_0067934) and 9 lncRNAs (LINC01433, MIAT, LINC01207, RNCR3, VPS9D1-AS1, ABHD11-AS1, SNHG16, NNT-AS1, PVT1).…”

Section: The Aberrant Expression Of Mir-1301 In Cancermentioning

confidence: 99%

“…All these ceRNAs can cause the down-regulation of miR-1301 expression ( Figure 3 ). The miR-1301-related ceRNA network exists in 11 cancers, including cervical cancer ( 33 ), esophageal cancer ( 12 , 38 , 39 ), LSCC ( 41 ),CRC ( 17 , 18 ), gastric cancer ( 1 ), OSCC ( 13 ), PTC ( 23 , 26 ), bladder cancer ( 28 ), ccRCC ( 27 ), osteosarcoma ( 43 ), and glioblastoma multiforme (GBM) ( 29 ).…”

Section: The Mir-1301-related Cerna Networkmentioning

confidence: 99%

“…Similarly, in CRC, RUNX1 activates RNCR3, and then RNCR3 promotes the occurrence and development of CRC through the RNCR3/miR-1301/AKT1 axis ( 17 ). In colon adenocarcinoma, VPS9D1-AS1 can promote tumor cell proliferation and invasion, and inhibit apoptosis through the VPS9D1-AS1/miR-1301-3p/CLDN1 axis ( 18 ). In gastric cancer, CTCF activates LINC01207 to promotes proliferation, migration, invasion of cancer cells, and inhibits apoptosis through the LINC01207/miR-1301/PODXL axis ( 1 ).…”

Section: The Mir-1301-related Cerna Networkmentioning

confidence: 99%

See 1 more Smart Citation

Aberrant Expression of miR-1301 in Human Cancer

et al. 2022

View full text Add to dashboard Cite

miR-1301 is a newly discovered miRNA, which is abnormally expressed in 14 types of tumors. miR-1301 inhibits 23 target genes, forms a ceRNA network with 2 circRNAs and 8 lncRNAs, and participates in 6 signaling pathways, thereby affecting tumor cell proliferation, invasion, metastasis, apoptosis, angiogenesis, etc. Abnormal expression of miR-1301 is often associated with poor prognosis of cancer patients. In addition, miR-1301 is related to the anti-tumor effect of epirubicin on osteosarcoma and imatinib on chronic myeloid leukemia(CML) and can enhance the cisplatin sensitivity of ovarian cancer. This work systematically summarizes the abnormal expression and prognostic value of miR-1301 in a variety of cancers, depicts the miR-1301-related signaling pathways and ceRNA network, and provides potential clues for future miR-1301 research.

show abstract

“…With the rapid development of modern medicine, significant breakthroughs have been made in basic research, early diagnosis, chemotherapy, and targeted therapy for colorectal cancer, yet the survival rate of colorectal cancer patients has not been significantly improved ( Durinikova et al, 2021 ). Colon adenocarcinoma (COAD) is a common malignant tumor among all types of colon cancer, with a high mortality rate and high recurrence rate ( Liu, 2021 ). Due to the lack of specific early diagnostic symptoms and markers, most patients were already at an advanced stage at the time of diagnosis, and the high metastatic rate characteristic of advanced COAD was a major factor in the high mortality rate of COAD patients ( Brown and Solomon, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection

Liang

Yao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Patients with colonic adenocarcinoma (COAD) are at relatively high risk of SARS-CoV-2 infection. However, there is a lack of medical strategies to treat COVID-19/COAD comorbidity. Puerarin, a natural product, is a known antiviral, antitumor, and immunomodulatory effect. Therefore, we hypothesised that puerarin could be used to treat COVID-19/COAD patients. Based on network pharmacology and bioinformatics analysis, the potential targets and pharmacological mechanisms of puerarin in COVID-19/COAD were identified. By intersecting therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes, 42 target genes of puerarin that could potentially treat COVID-19/COAD comorbidity were obtained. By using the 42 potential target genes to construct the protein-protein interaction (PPI) network, we obtained five core target genes, namely RELA, BCL2, JUN, FOS, and MAPK1. The results of bioinformatics analysis revealed that puerarin could be able to treat COVID-19/COAD comorbidity through apoptosis, antiviral, antioxidant, NF-κB signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway etc. This study found that puerarin has the potential to treat COVID-19/COAD patients and that the therapeutic target genes obtained in the study may provide clues for the treatment of COVID19/COAD comorbidity.

show abstract

RETRACTED ARTICLE: Long non-coding RNA VPS9D1-AS1 promotes growth of colon adenocarcinoma by sponging miR-1301-3p and CLDN1

Cited by 8 publications

References 52 publications

A novel necroptosis-related lncRNAs signature effectively predicts the prognosis for osteosarcoma and is associated with immunity

A novel necroptosis-related lncRNAs signature effectively predicts the prognosis for osteosarcoma and is associated with immunity

Aberrant Expression of miR-1301 in Human Cancer

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection

Contact Info

Product

Resources

About